Garcinol / IL6 Cancer Research Results

GAR, Garcinol: Click to Expand ⟱
Features:
Found in dried fruit rind of Garcinia Indica with anti-inflammatory, antioxidant, anticancer, and antibacterial properties
Garcinia Cambogia Extract.
"We conclude that patients who are T-cadherin-positive could especially benefit from a therapy with garcinol."

🔬1) NF-κB & AP-1 Suppression
Garcinol inhibits NF-κB and AP-1 transcriptional activity in multiple cancer cell systems, reducing pro-inflammatory and pro-survival gene expression.
📚 2) Epigenetic Regulation
Garcinol is one of the few natural products shown to inhibit p300/CBP histone acetyltransferases, shifting chromatin acetylation and influencing gene expression (differentiation, apoptosis, EMT). This is more specific than general “HDAC modulation.”
💀 3) Apoptosis
Studies report modulation of the Bcl-2 family and increased caspase activity, but this is often downstream of transcription/epigenetic changes, not a direct redox trigger.
🧬 4) Cell Cycle & Proliferation
Lower Cyclin D1, higher p21/p27, and G1/S arrest are common phenotypes.
🧭 5) Invasion & Angiogenesis
Garcinol reduces MMP-2/9 and angiogenic markers in multiple tumor cell assays.

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NF-κB / AP-1 signaling NF-κB ↓; AP-1 ↓; downstream pro-survival/inflammatory outputs ↓ ↔ or anti-inflammatory modulation in immune cells R, G Pro-survival & inflammatory transcription suppression Garcinol is reported to inhibit NF-κB and AP-1 transcriptional activity, reducing inflammation and pro-growth signaling in multiple models.
2 Epigenetic regulation (HAT/HDAC modulation) Inhibition of p300/CBP histone acetyltransferase; altered acetylation patterns ↔ baseline epigenetic state R, G Gene regulatory reprogramming Garcinol directly inhibits histone acetyltransferases (especially p300/CBP), influencing chromatin state and gene expression linked to differentiation and proliferation.
3 Intrinsic apoptosis (mitochondrial / caspase-linked) ↑ Bax/Bak; ↓ Bcl-2/Bcl-xL; ↑ caspase-9/3 ↔ minimal activation in normal cells G Execution of apoptosis Often downstream of stress and survival pathway modulation; not as dominant as classic pro-oxidant molecules but consistent in many cell lines.
4 Cell-cycle checkpoints (p21/p27; Cyclin D1) Cell-cycle arrest (often G1/S); Cyclin D1 ↓ ↔ G Cytostasis Frequently reported as later phenotypic outcome tied to reduced proliferation.
5 Invasion / metastasis programs (MMPs / EMT) MMP-2/9 ↓; invasion/migration ↓; EMT markers ↓ ↔ G Anti-invasive phenotype Linked mechanistically to NF-κB/AP-1 and epigenetic changes influencing MMP expression and EMT regulators.
6 Angiogenesis signaling (VEGF & pro-angiogenic factors) VEGF ↓; pro-angiogenic markers ↓ ↔ G Anti-angiogenic support Sometimes measured in later in vivo or emulated assay systems; reflects downstream gene expression changes.
7 PI3K/AKT / survival kinases ↓ PI3K/AKT signaling (model-dependent) ↔ R, G Survival/growth suppression Modulation of survival kinases is reported in some systems but not a universal primary mechanism.
8 ROS / oxidative stress (context–dependent) ROS modulation (inconsistent across models) ↔ P, R, G Conditional stress modulation Some studies report mild ROS changes, but garcinol is not a strong pro-oxidant driver like BetA or curcumin in cancer cells.
9 Chemo-sensitization / combination relevance Enhanced sensitivity to chemotherapeutics (context) — G Combination leverage Combination effects are reported in selected cell lines/model systems; not universal.
10 Bioavailability constraint (oral exposure / formulation dependence) Systemic exposure often limited without enhanced delivery — — Translation constraint Poor native bioavailability is common across polyphenols/bzp molecules; formulations improve systemic exposure.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (primary/physical-chemical effects; rapid signaling / kinase shifts)
  • R: 30 min–3 hr (acute stress-response and transcription signaling)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
IL6, Interleukin-6: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Interleukin-6 (IL-6) is a cytokine that plays a significant role in inflammation and the immune response. It is produced by various cell types, including T cells, B cells, macrophages, and fibroblasts.
IL-6 can promote tumor cell proliferation and survival. Many cancer cells produce IL-6, which can create an autocrine loop that supports their growth.
IL-6 is a high-value inflammatory biomarker in cancer, reporting cytokine burden, catabolic stress, and STAT3-linked survival signaling. While not tumor-specific, elevated and rising IL-6 strongly predicts poor prognosis and limited treatment tolerance, making it an important system-state indicator alongside CRP and ferritin.


Scientific Papers found: Click to Expand⟱
805- GAR,  Cisplatin,  PacT,    Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells
- Review, NA, NA
ERK↓, PI3K/Akt↓, Wnt/(β-catenin)↓, STAT3↓, NF-kB↓, ChemoSen↑, COX2↓, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, VEGF↓, TGF-β↓, HATs↓, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↓, Let-7↑, MMP9↓, TumCCA↑, ROS↑, MMP↓, IL6↓, NOTCH1↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

PI3K/Akt↓, 1,  

Cell Death ⓘ

BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp9↑, 1,  

Transcription & Epigenetics ⓘ

HATs↓, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   Let-7↑, 1,   NOTCH1↓, 1,   STAT3↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   MMP9↓, 1,   TGF-β↓, 1,   Vim↓, 1,   Zeb1↓, 1,   ZEB2↓, 1,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL6↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  
Total Targets: 26

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: IL6, Interleukin-6
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:83  Target#:158  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page